Venture Report: Pair of crossover rounds for precision oncology, peptide biotechs

A pair of companies raised crossover rounds this week, with the biggest coming from precision oncology play IDRx, while three more high profile new companies emerged from stealth in the past couple of weeks. 

IDRx Inc., which is developing KIT inhibitor IDRX-42 for GIST, raised $120 million in a series B round co-led by RA Capital, Commodore Capital and Blackstone Multi-Asset Investing. The biotech plans to use the funds to support an ongoing Phase I study of IDRX-42 and a planned pivotal study in second-line GIST...